Bacteriology Market Analysis and Reports | Canada Conference Series

Market Analysis - Bacteriology 2019

Market Analysis

The Bacteriology industry totalled nearly $7.7 billion in 2012. This total is expected to grow from $8.5 billion in 2013 to $11.4 billion in 2018, with a compound annual growth rate (CAGR) of 6.1% for the five-year period, 2013 to 2018. According to the Centers for Disease Control and Prevention (CDC), in the U.S. alone, a total of 23.6 million cases of infectious and parasitic diseases were reported in 2010. Microbiology culture is efficient diagnosis method to detect cause of infectious diseases its application in the production of antibiotic drugs is witnessing a remarkable rise, worldwide.

Importance and Scope:

Bacteriology is one of the important terms in the field of microbiology. Since bacteria are present almost everywhere, the need to discover new drugs, antibiotics and vaccines are under pressure. Since some of the bacteria can cause severe infections and diseases, the importance to study about them in depth is necessary. The scope of this field is vast since the evolution of bacteria to the level of multidrug resistance is threating thus leading researchers to find new antibiotics and medicines. Bacteria have a vital role in the scope of genetic engineering because the genetically engineered bacteria can be used for the production of new drugs and agricultural crops improved by the genetic engineering. There is a need for the development of new drugs and techniques to produce new drugs since the infectious diseases are increasing in number and the virulence factor is progressing rapidly.

Common Infectious Diseases and Antibiotics:


Bacterial Infection










Bacterial meningitis


Otitis media


Urinary tract infection (UTI)


Respiratory tract infection



Top Companies Manufacturing Antibiotics:

  • Pfizer
  • Merck and Co
  • Johnson and Johnson
  • GlaxoSmithKline
  • Bristol-Meyers Squibb
  • Aventis
  • Pharmacia
  • Novartis
  • F. Hoffmann-La Roche
  • Astra Zeneca
  • Abott Laboratories
  • Wyeth
  • Eli Lilly and Co
  • Schering Plough
  • Bayer


America Region

The antibiotics market was valued at USD 39.8 million in 2015 and is expected to witness a CAGR of 4.0% over the forecast period. Increasing efforts are being witnessed toward the development of advanced products. According to the data published by the Pew Charitable Trust, in March 2016, about 37 promising molecules were being investigated within the U.S. market. Majority of these, are in phase II clinical trials and are anticipated to hit the market between 2018 - 2020

The antibiotics market is expected to reach USD 57.0 billion by 2024, according to the new report by Grand View Research, Inc. Rising prevalence of infectious diseases especially in developing regions such as Asia Pacific and MEA is anticipated to contribute towards market growth. North America dominated the animal antimicrobials and antibiotics markets. However, the market share of this region will decrease to 27%, primarily due to the regulatory ban on the use of antibiotics announced in the U.S. At the same time, Asia and Latin America are poised to grow at a CAGR of 6% to 8% in the forecast period; this growth is largely driven by the increased urbanization, rising disposable incomes, increase in the demand for animal products and the increasing trend of pet ownerships in these regions.

 More than 15.0% of the deaths, in children below the age of five, are estimated to be due to pneumonia and according to the statistics provided by the WHO about 9.2 million deaths were recorded

Europe Region

Antibiotic resistance is a serious problem globally. New antibiotics to tackle resistant bacteria are urgently needed; however, a recent report from the European Centre for Disease Prevention and Control and the European Medicines Agency (EMA) warns of an almost empty pipeline, leaving patients vulnerable to dangerous infections. If new antibiotics are not developed, the entire healthcare industry could face challenges not seen since the pre-bacteria era. Public-private partnerships are encouraging specific programs that will address these needs; in certain regions, government agencies are working with the pharmaceutical industry to provide support to the declining antibiotic pipeline. “Development of novel antibiotics to combat multidrug-resistant strains, and targeting non-multiplying bacteria are expected to play a vital role in market growth,”

Asia pacific Region

The global market for systemic antibiotics is expected to grow to $41.2 billion by 2018 with a compound annual growth rate (CAGR) of 0.8% between 2013 through 2018. Asian countries account for the fastest-growing market with a five-year CAGR of 1.2% due to the increasing aging population, increasing GDP rate and increasing awareness about healthcare.

The global systemic antibiotics market is primarily driven by the aging population worldwide, the increasing prevalence of hospital-acquired infections, and the resultant increase in infectious disease and rising demand for novel antibiotics from the pharmaceutical industry.

Nevertheless, a major paradigm shift in the regulatory framework has caused a positive impact on the overall growth of the antibiotics market. Economic conditions and cost-containment issues have compelled North American and European antibiotic manufacturers to explore new regions, such as India, China and Brazil, for growth opportunities.

Middle East Region

The use of antimicrobial agents in food-producing animals has recently become a very important public health issue. The Middle-East & Africa market for anticoccidial drugs is estimated to grow from $163.1 million in 2015 to $218 Million by 2020 at a CAGR of 5.95% The Middle-East & Africa anticoccidial drugs market is classified based on various types of animals and by type of antibiotics.The region, especially countries like Saudi Arabia and Egypt, has increased its reliance on antibiotics.The antibiotics market analysis by drug class, Mechanism of action, and segment forecasts 2015-2024 anticipated to gain CAGR of 4.0%